...survival (OS). XBIO-101 is a small molecule immunomodulator and interferon inducer that increases PGR expression. Xenetic... ...excluding oncology indications (see BioCentury, Dec. 21, 2015 ). Pharmsynthez JSC (MICEX:LIFE), Saint Petersburg, Russia Xenetic Biosciences Inc.... ...PFS), duration of stable disease and overall survival (OS) Status: Phase II started Milestone: NA
Julian Zhu
Xenetic Biosciences Inc.
Progesterone...
...weeks and levels were maintained in the range for the remainder of the 17-week study. Xenetic... ...cohorts of the trial (see BioCentury, Aug. 3, 2015 ). SynBio has rights to co-develop Xenetic’s... ...in Russia, while Serum Institute has co-development rights in India. SynBio LLC , Moscow, Russia Xenetic Biosciences Inc....
...$4. Xenetic will transfer its listing to NASDAQ, effective Nov. 7. Xenetic Biosciences Inc. (OTCQB:XBIO), Lexington, Mass.
Alicia Parker
Xenetic Biosciences Inc....
...raised: Up to $10 million Units: 2.5 million Price Prior: $0.24 Underwriter: Ladenburg Thalmann Note: Xenetic... ...up to $10 million. The company filed to raise up to $20 million in May. Xenetic...
...be raised: Up to $10 million Units: TBD Price Prior: $0.24 Underwriter: Ladenburg Thalmann Note: Xenetic... ...converts into one share. The company filed to raise up to $20 million in May. Xenetic...
...Excivion partnered to develop a Zika and dengue virus vaccine combination. The companies will use Xenetic’s... ...own resulting IP. The companies declined to disclose financial terms. Excivion Ltd. , Cambridge, U.K. Xenetic Biosciences Inc....
...raised: Up to $15 million Units: 3 million Price Prior: $0.24 Underwriter: Ladenburg Thalmann Note: Xenetic... ...to purchase a share. The company filed to raise up to $20 million in May. Xenetic...
...survival (OS). XBIO-101 is a small molecule immunomodulator and interferon inducer that increases PGR expression. Xenetic... ...excluding oncology indications (see BioCentury, Dec. 21, 2015 ). Pharmsynthez JSC (MICEX:LIFE), Saint Petersburg, Russia Xenetic Biosciences Inc.... ...PFS), duration of stable disease and overall survival (OS) Status: Phase II started Milestone: NA
Julian Zhu
Xenetic Biosciences Inc.
Progesterone...
...weeks and levels were maintained in the range for the remainder of the 17-week study. Xenetic... ...cohorts of the trial (see BioCentury, Aug. 3, 2015 ). SynBio has rights to co-develop Xenetic’s... ...in Russia, while Serum Institute has co-development rights in India. SynBio LLC , Moscow, Russia Xenetic Biosciences Inc....
...$4. Xenetic will transfer its listing to NASDAQ, effective Nov. 7. Xenetic Biosciences Inc. (OTCQB:XBIO), Lexington, Mass.
Alicia Parker
Xenetic Biosciences Inc....
...raised: Up to $10 million Units: 2.5 million Price Prior: $0.24 Underwriter: Ladenburg Thalmann Note: Xenetic... ...up to $10 million. The company filed to raise up to $20 million in May. Xenetic...
...be raised: Up to $10 million Units: TBD Price Prior: $0.24 Underwriter: Ladenburg Thalmann Note: Xenetic... ...converts into one share. The company filed to raise up to $20 million in May. Xenetic...
...Excivion partnered to develop a Zika and dengue virus vaccine combination. The companies will use Xenetic’s... ...own resulting IP. The companies declined to disclose financial terms. Excivion Ltd. , Cambridge, U.K. Xenetic Biosciences Inc....
...raised: Up to $15 million Units: 3 million Price Prior: $0.24 Underwriter: Ladenburg Thalmann Note: Xenetic... ...to purchase a share. The company filed to raise up to $20 million in May. Xenetic...